Molecular Partners AG, a biotechnology company, engages in the discovery and development of Designed Ankyrin Repeat Proteins (DARPins) based on the designed repeat protein technology. The company focuses on therapeutic, diagnostic, and biotechnological applications of DARPins. DARPins are binding proteins that show activity against various disease targets, including cell surface receptors, cytokines, proteases, kinases, and viral coat proteins. The company was incorporated in 2004 and is based in Zurich, Switzerland.
Funding Rounds (2) - $59.76MUpdate
|BB Biotech Ventures||Series A|
|Endeavour Vision||Series A|
|Essex Woodlands Health Ventures||Series B (Lead)|
|Index Ventures||Series A (Lead)|
|Johnson & Johnson Development Corporation||Series A||-|
Current Team (4)Update